MDM2 induces NF-κB/p65 expression transcriptionally through Sp1-binding sites: A novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia

Blood

Volumn 99, Issue 9, 2002, Pages 3367-3375

  Gu, Lubing ^a   Findley, Harry W ^a   Zhou, Muxiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MDM2; PROTEIN P53; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR SP1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CHROMATIN; ELECTROPHORETIC MOBILITY; GENE ACTIVITY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; TRANSCRIPTION REGULATION;

EID: 0036565875     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3367     Document Type: Article

References (60)

1. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
2. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
3. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53
4. Mapping of the p53 and mdm2 interaction domains
5. The p53-associated protein MDM2 contains a newly characterized zinc-finger domain called the RING finger
6. Stimulation of E2F1/DP1 transcriptional activity by MDM2 onco-protein
7. Interaction between the retinoblastoma protein and the onco-protein MDM2
8. Disruption of I kappa B alpha regulation by antisense RNA expression leads to malignant transformation
9. Oncogenic Ha-Ras-induced signaling activates NFκB transcriptional activity, which is required for cellular transformation
10. Rel/NF-κB transcription factors and the control of apoptosis
11. Iκβ: A specific inhibitor of the NFκB transcription factor
12. NfκB: Ten years after
13. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer
14. The nuclear factor-kappa B Rel A transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
15. Constitutive activation of NFκB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells
16. An essential role for NF-κB in preventing TNF-α-induced cell death
17. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NFκB
18. Suppression of TNF-α-induced apoptosis by NFκB
19. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death
20. Structure, regulation and function of NF-kappa B
21. Independent modes of transcriptional activation by the p50 and p65 subunits of NFκB
22. Cloning of an NFκB subunit which stimulates HIV transcription in synergy with p65
23. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B
24. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality
25. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression
26. The NF-κB transcription factor in oncogenesis
27. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
28. The NF-kappa B and I kappa B proteins: New discoveries and insights
29. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-κB promoters
30. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV-40 early promoter
31. Cip1/waf-1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites
32. waf1/cip1/sdl1 gene by c-Jun through Sp1 site
33. The NFκB p65 promoter
34. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene
35. Tumor necrosis factor α-induced E-selectin expression is activated by the nuclear factor-κB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways
36. Rb interacts with histone deacetylase to repress transcription
37. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia
38. NFκB antiapoptosis: Induction of TRAF1 and TRAF2 and clAP1 and c-lAP2 to suppress caspase-8 activation
39. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-lAP2 is under NF-κB control
40. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis
41. Nuclear factor-κB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor necrosis factor α-induced apoptosis
42. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300
43. Transcriptional cross talk between NF-κB and p53
44. CREB-binding protein is a nuclear integrator of nuclear factor-KB and p53 signaling
45. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis
46. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia
47. Wild-type p53 can down-modulate the activity of various promoters
48. Growth suppression induced by wild-type p53 protein is aocompanied by selective down-regulation of proliferating-cell nuclear antigen expression
49. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression
50. p53 represses Sp1 DNA binding and HIV-LTR directed transcription
51. SV40 stimulates expression of the trans-acting factor Sp1 at the mRNA levels
52. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase
53. PRB induces Sp1 activity by relieving inhibition mediated by MDM2
54. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein
55. Cell type-specific inhibition of p53-mediated apoptosis by mdm2
56. Caspases: Enemies within
57. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma
58. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis
59. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities
60. MDM2 mRNA level is a prognostic factor in soft tissue sarcoma